Log in

Relevant bibliographies by topics / Metal-based drugs

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Metal-based drugs'

Author: Grafiati

Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Metal-based drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Metal-based drugs"

1

Mcquitty, Ruth J. "Metal-based Drugs." Science Progress 97, no. 1 (March 2014): 1–19. http://dx.doi.org/10.3184/003685014x13898980185076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dyson, Paul J. "Metal-based Drugs." Australian Journal of Chemistry 63, no. 11 (2010): 1503. http://dx.doi.org/10.1071/ch10382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey, and Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs." Current Topics in Medicinal Chemistry 11, no. 5 (March 1, 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sava, Gianni. "Metal Based Drugs Restyled and Resumed." Metal-Based Drugs 2007 (March 25, 2007): 1. http://dx.doi.org/10.1155/2007/16260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Timerbaev, Andrei R., and Bernhard K. Keppler. "Capillary electrophoresis of metal-based drugs." Analytical Biochemistry 369, no. 1 (October 2007): 1–7. http://dx.doi.org/10.1016/j.ab.2007.05.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Vlasiou, Manos. "In Search of Antiviral Metal-Based Drugs." Open Medicinal Chemistry Journal 15, no. 1 (December 31, 2021): 30–31. http://dx.doi.org/10.2174/1874104502015010030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Allardyce, Claire S., and Paul J. Dyson. "Metal-based drugs that break the rules." Dalton Transactions 45, no. 8 (2016): 3201–9. http://dx.doi.org/10.1039/c5dt03919c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fricker, Simon Paul. "Metal based drugs: from serendipity to design." Dalton Transactions, no. 43 (2007): 4903. http://dx.doi.org/10.1039/b705551j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Aderibigbe, B. A. "Polymeric Prodrugs Containing Metal-Based Anticancer Drugs." Journal of Inorganic and Organometallic Polymers and Materials 25, no. 3 (April 4, 2015): 339–53. http://dx.doi.org/10.1007/s10904-015-0220-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Reisner, Erwin, Vladimir B. Arion, Bernhard K. Keppler, and Armando J. L. Pombeiro. "Electron-transfer activated metal-based anticancer drugs." Inorganica Chimica Acta 361, no. 6 (May 2008): 1569–83. http://dx.doi.org/10.1016/j.ica.2006.12.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Metal-based drugs"

1

Martin, Elisabeth Katharina [Verfasser], and Eric [Akademischer Betreuer] Meggers. "Development of a New Generation of Metal-Based Anticancer Drugs / Elisabeth Katharina Martin ; Betreuer: Eric Meggers." Marburg : Philipps-Universität Marburg, 2019. http://d-nb.info/1192441648/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Anand, Resmi <1984&gt. "Spectroscopic studies on Cyclodextrin and Metal Organic Framework based potential nanovectors for delivery of Anticancer and Antiviral drugs." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5698/1/ANAND_RESMI_tesi.pdf.

Full text

Abstract:

The aim of this work is to contribute to the development of new multifunctional nanocarriers for improved encapsulation and delivery of anticancer and antiviral drugs. The work focused on water soluble and biocompatible oligosaccharides, the cyclodextrins (CyDs), and a new family of nanostructured, biodegradable carrier materials made of porous metal-organic frameworks (nanoMOFs). The drugs of choice were the anticancer doxorubicin (DOX), azidothymidine (AZT) and its phosphate derivatives and artemisinin (ART). DOX possesses a pharmacological drawback due to its self-aggregation tendency in water. The non covalent binding of DOX to a series of CyD derivatives, such as g-CyD, an epichlorohydrin crosslinked b-CyD polymer (pb-CyD) and a citric acid crosslinked g-CyD polymer (pg-CyD) was studied by UV visible absorption, circular dichroism and fluorescence. Multivariate global analysis of multiwavelength data from spectroscopic titrations allowed identification and characterization of the stable complexes. pg-CyD proved to be the best carrier showing both high association constants and ability to monomerize DOX. AZT is an important antiretroviral drug. The active form is AZT-triphosphate (AZT-TP), formed in metabolic paths of low efficiency. Direct administration of AZT-TP is limited by its poor stability in biological media. So the development of suitable carriers is highly important. In this context we studied the binding of some phosphorilated derivatives to nanoMOFs by spectroscopic methods. The results obtained with iron(III)-trimesate nanoMOFs allowed to prove that the binding of these drugs mainly occurs by strong iono-covalent bonds to iron(III) centers. On the basis of these and other results obtained in partner laboratories, it was possible to propose this highly versatile and “green” carrier system for delivery of phosphorylated nucleoside analogues. The interaction of DOX with nanoMOFs was also studied. Finally the binding of the antimalarial drug, artemisinin (ART) with two cyclodextrin-based carriers,the pb-CyD and a light responsive bis(b-CyD) host, was also studied.

APA, Harvard, Vancouver, ISO, and other styles

3

Anand, Resmi <1984&gt. "Spectroscopic studies on Cyclodextrin and Metal Organic Framework based potential nanovectors for delivery of Anticancer and Antiviral drugs." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5698/.

Full text

Abstract:

The aim of this work is to contribute to the development of new multifunctional nanocarriers for improved encapsulation and delivery of anticancer and antiviral drugs. The work focused on water soluble and biocompatible oligosaccharides, the cyclodextrins (CyDs), and a new family of nanostructured, biodegradable carrier materials made of porous metal-organic frameworks (nanoMOFs). The drugs of choice were the anticancer doxorubicin (DOX), azidothymidine (AZT) and its phosphate derivatives and artemisinin (ART). DOX possesses a pharmacological drawback due to its self-aggregation tendency in water. The non covalent binding of DOX to a series of CyD derivatives, such as g-CyD, an epichlorohydrin crosslinked b-CyD polymer (pb-CyD) and a citric acid crosslinked g-CyD polymer (pg-CyD) was studied by UV visible absorption, circular dichroism and fluorescence. Multivariate global analysis of multiwavelength data from spectroscopic titrations allowed identification and characterization of the stable complexes. pg-CyD proved to be the best carrier showing both high association constants and ability to monomerize DOX. AZT is an important antiretroviral drug. The active form is AZT-triphosphate (AZT-TP), formed in metabolic paths of low efficiency. Direct administration of AZT-TP is limited by its poor stability in biological media. So the development of suitable carriers is highly important. In this context we studied the binding of some phosphorilated derivatives to nanoMOFs by spectroscopic methods. The results obtained with iron(III)-trimesate nanoMOFs allowed to prove that the binding of these drugs mainly occurs by strong iono-covalent bonds to iron(III) centers. On the basis of these and other results obtained in partner laboratories, it was possible to propose this highly versatile and “green” carrier system for delivery of phosphorylated nucleoside analogues. The interaction of DOX with nanoMOFs was also studied. Finally the binding of the antimalarial drug, artemisinin (ART) with two cyclodextrin-based carriers,the pb-CyD and a light responsive bis(b-CyD) host, was also studied.

APA, Harvard, Vancouver, ISO, and other styles

4

Tabata, Yasuhiko. "Drug targeting through polymer conjugation based on metal coordination." 京都大学 (Kyoto University), 2003. http://hdl.handle.net/2433/148611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Nomkoko, Thembelani Edmund. "Computer-aided chemical speciation in metal-based drug design." Doctoral thesis, University of Cape Town, 2002. http://hdl.handle.net/11427/21347.

Full text

Abstract:

Formation constants of Cu²⁺, Ni²⁺, Zn²⁺, Ca²⁺ and Gd³⁺ with the polyamine(amide) ligands N,N' -bis(2-hydroxyiminopropionyl) propane-1,3-diamine (L² ) and (1, 15)- bis(N,N-dimethyl)-5, 11-dioxo-8-(N-benzyl)-l ,4,8, 12, 15-pentaazapentadecane (L³ ) as well as those of Gd³⁺ with 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioxime (L 1 ) were investigated by glass electrode potentiometry at 25°C and an ionic strength (I) of 0.15 mol dm-³.

APA, Harvard, Vancouver, ISO, and other styles

6

Roth, Kristina L. "Development of Metal-based Nanomaterials for Biomedical Applications." Diss., Virginia Tech, 2017. http://hdl.handle.net/10919/85365.

Full text

Abstract:

New synthetic advances in the control of nanoparticle size and shape along with the development of new surface modifications facilitates the growing use of nanomaterials in biomedical applications. Of particular interest are functional and biocompatible nanomaterials for sensing, imaging, and drug delivery. The goal of this research is to tailor the function of nanomaterials for biomedical applications by improving the biocompatibility of the systems. Our work demonstrates both a bottom up and a post synthetic approach for incorporating stability, stealth, and biocompatibility to metal based nanoparticle systems. Two main nanomaterial projects are the focus of this dissertation. We first investigated the development of a green synthetic procedure to produce gold nanoparticles for biological imaging and sensing. The size and morphology of gold nanoparticles directly impact their optical properties, which are important for their function as imaging agents or their use in sensor systems. In this project, a synthetic route based on the natural process of biomineralization was developed, where a designed protein scaffold initiates the nucleation and subsequent growth of gold ions. To gain insight into controlling the size and morphology of the synthesized nanoparticles, interactions between the gold ions and the protein surface were studied along with the effect of ionic strength on interactions and then subsequent crystal growth. We are able to control the size and morphology of the gold nanoparticles by altering the concentration or identity of protein scaffold, salt, or reducing agent. The second project involves the design and optimization of metal organic framework nanoparticles for an external stimulus triggered drug delivery system. This work demonstrates the advantages of using surface coatings for improved stability and functionalization. We show that the addition of a polyethylene glycol surface coating improved the colloidal stability and biocompatibility of the system. The nanoparticle was shown to successfully encapsulate a variety of small molecule cargo. This is the first report of photo-triggered degradation and subsequent release of the loaded cargo as a mechanism of stimuli-controlled drug delivery. Each of the aforementioned projects demonstrates the design, synthesis, and optimization of metal-based systems for use in biomedical applications.
Ph. D.

APA, Harvard, Vancouver, ISO, and other styles

7

Binks, Stephen Peter. "Absorption, toxicity and deposition of transition metal based pharmaceuticals following oral administration." Thesis, University of Surrey, 1988. http://epubs.surrey.ac.uk/847165/.

Full text

Abstract:

The aim of this dissertation was to study the absorption, and subsequent toxic side effects of transition metal based pharmaceuticals following oral administration to rats. Administration of cisplatin (30mg/kg), carboplatin (37mg/kg) and iproplatin (42mg/kg) by oral gavage resulted in their rapid absorption so that respective peak blood levels of 2.63mug platinum/ml, 1.48mug platinum/ml and 3.13mug platinum/ml were achieved within 2-4 hours. Approximately 3-4% of the dose was excreted in the urine, but the major route of elimination was the faeces (>75%). This indicated that although rapid, absorption was relatively poor. Absorption was enhanced by employing a period of starvation prior to administration. A series of novel platinum (IV) mixed amines were absorbed to a greater extent than cisplatin and its congeners, carboplatin and iproplatin. However, absorption was somewhat slower with peak blood levels being attained some 24 hours after administration. Of the other transition metal complexes studied, auranofin and ruthenium acetylacetonate were particularly well absorbed so that peak blood levels of 12.53mug gold/ml and 6.4mug ruthenium/ml were achieved respectively. Urinary clearance of the ruthenium complex was especially significant with up to 45% of the administered dose being eliminated by this pathway within 48 hours. In vitro everted gut sac and in situ perfusion techniques confirmed the in vivo finding that cisplatin is absorbed from the small intestine more readily than carboplatin. No evidence for active or carrier-mediated transport was found and kinetic studies confirmed that absorption was by passive diffusion. Toxicology studies after oral administration of cisplatin (57 or 30mg/kg) or carboplatin (282mg/kg) indicated that the toxicities associated with the perenteral use of the complexes would also apply to the oral route. This was exemplified by the fact that oral cisplatin was profoundly nephrotoxic, whereas carboplatin was not. In addition, gastro-intestinal toxicity manifested as acute necrotizing enteritis and ulcerogenicity of the stomach was potentiated by the oral route. Studies in the ferret indicated that cisplatin is significantly more emetogenic than carboplatin. Examination of liver morphology indicated changes, such as mitochondrial swelling and vesiculation of the endoplasmic reticulum, that might indicate a higher incidence of hepatotoxic responses associated with administration of platinum complexes by the oral route. Both cisplatin and carboplatin induced a degree of myelosuppression but the most pronounced haematological lesion associated with oral administration was severe erythrocytosis which occurred as a result of a dehydration related decrease in plasma volume. Electrothermal atomic absorption analysis of tissues excised from cisplatin and carboplatin rats indicated that platinum deposition was highest in the kidney. In an attempt to explain the prolonged retention of cisplatin in this organ, the intracellular location of the compound was studied using electron microprobe analysis and subcellular fractionation. The various lysosome populations of the proximal tubule were identified as sites of concentration of platinum and it was hypothesised that sequestration within these organelles might be an important mechanism of detoxification.

APA, Harvard, Vancouver, ISO, and other styles

8

Dan, Mo. "THE PHARMACOKINETICS OF METAL-BASED ENGINEERED NANOMATERIALS, FOCUSING ON THE BLOOD-BRAIN BARRIER." UKnowledge, 2013. http://uknowledge.uky.edu/pharmacy_etds/21.

Full text

Abstract:

Metal-based engineered nanomaterials (ENMs) have potential to revolutionize diagnosis, drug delivery and manufactured products, leading to greater human ENM exposure. It is crucial to understand ENM pharmacokinetics and their association with biological barriers such as the blood-brain barrier (BBB). Physicochemical parameters such as size and surface modification of ENMs play an important role in ENM fate, including their brain association. Multifunctional ENMs showed advantages across the highly regulated BBB. There are limited reports on ENM distribution among the blood in the brain vasculature, the BBB, and brain parenchyma. In this study, ceria ENM was used to study the effect of size on its pharmacokinetics. Four sizes of ceria ENMs were studied. Five nm ceria showed a longer half-life in the blood and higher brain association compared with other sizes and 15 and 30 nm ceria had a higher blood cell association than 5 or 55 nm ceria. Because of the long circulation and high brain association of 5 nm ceria compared with other sizes, its distribution between the BBB and brain parenchyma was studied. The in situ brain perfusion technique showed 5 nm ceria (99%) on the luminal surface of the BBB rather than the brain parenchyma. For biomedical applications in the central nervous system (CNS), it is vital to develop stable and biocompatible ENMs and enhance their uptake by taking advantage of their unique properties. Cross-linked nanoassemblies entrapping iron oxide nanoparticles (CNA-IONPs) showed controlled particle size in biological conditions and less toxicity in comparison to Citrate-IONPs. CNA-IONPs considerably enhanced MRI T2 relaxivities and generated heat at mild hyperthermic temperatures (40 ~ 42°C) in the presence of alternating magnetic field (AMF). Numerous researchers showed mild whole body hyperthermia can increase BBB permeability for potential brain therapeutic application. Compared to conventional hyperthermia, AMF-induced hyperthermia increased BBB permeability with a shorter duration of hyperthermia and lower temperature, providing the potential to enhance IONP flux across the BBB with reduced toxicity. Overall, ENMs with optimized physicochemical properties can enhance their flux across the BBB into the brain with desirable pharmacokinetics, which provide great potential for diagnosis and therapy in the CNS.

APA, Harvard, Vancouver, ISO, and other styles

9

Faustino, Brissos Rosa Maria. "Coordination, organometallic and supramolecular chemistry approaches to the design of metal-based cytotoxic agents." Doctoral thesis, Universitat de Barcelona, 2018. http://hdl.handle.net/10803/544129.

Full text

Abstract:

The discovery of cisplatin and its successful use as chemotherapeutic agent have encouraged the development of metal-based anticancer molecules. The present doctoral research project includes three different chemistry approaches to design new metal-based cytotoxic compounds. Coordination, organometallic and supramolecular chemistry have been used to successfully develop three families of compounds with highly promising biological properties. Copper(II) coordination compounds of various nuclearities have been prepared from new Schiff-base ligands. The complexes strongly interact with DNA without cleaving it and exhibit notable cytotoxicities against various murine and human cancer cell lines. Organometallic ruthenium(II)-arene compounds containing a monophosphane PR3 ligand have been obtained, which show remarkable cytotoxicites against a wide panel of human cancer cells, so as very interesting antimetastatic properties. Structureactivity relationship studies have been carried out, which illustrated the great potential (and versatility) of this family of molecules, whose biological properties can be finetuned by the selection of the different ligands bound to the metal. A new family of supramolecular compounds has been developed with the objective to target the DNA major groove or/and stabilize non-conventional DNA structures, for instance the three-way junction (3WJ). The series of iron(III) metallohelicates prepared exhibit groove-binding properties but are not capable of stabilizing the 3WJ. Some of these helical complexes show interesting cytotoxic properties and one of them can even induce cell apoptosis.
El descobriment que cisplatí és un fàrmac molt útil en quimioteràpia ha encoratjat el desenvolupament de fàrmacs antitumorals basats en metalls. El projecte de recerca d’aquesta Tesi Doctoral inclou tres aproximacions diferents pel disseny de nous compostos citotòxics basats en metalls. Així doncs, tant la química de coordinació com l’organometàl·lica i supramolecular s’han emprat per desenvolupar tres famílies de compostos amb propietats biològiques molt prometedores. S’han preparat complexos de Cu(II) amb imines (bases de Shiff) de diverses nuclearitats. S’ha trobat que els complexos interaccionen fortament amb l’ADN sense escindir-lo i tenen citotoxicitats elevades en diverses línies de cèl·lules canceroses de ratolí i també humanes. S’han estudiat també compostos organometàl·lics de Ru(II) amb fosfines terciàries PR3 i s’ha trobat que són molt citotòxics en un ampli espectre de línies cel·lulars canceroses humanes. A més, presententen un efecte antimetastàtic molt interessant. S’han establert relacions estructura-propietat, fet que il·lustra el gran potencial i versatilitat d’aquesta família de molècules perquè les propietats es poden modular segons el lligand fosfina unit al metall. Finalment, s’ha desenvolupat una nova família de compostos supramoleculars amb l’objectiu que interaccionin amb el solc gran de l’ADN i/o estabilitzar estructures no convencionals de l’ADN com per exemple unions triples (3WJ). Així doncs, s’ha trobat que els metal·lohelicats de Fe(III) que s’han preparat s’uneixen al solc major de l’ADN però no son capaços d’estabilitzar les unions triples 3WJ. Alguns d’aquests compostos presenten propietats citotòxiques interessants i un d’ells fins i tot indueix l’apoptosi cel·lular.

APA, Harvard, Vancouver, ISO, and other styles

10

Cirri, Damiano. "Metal based drugs with potential anticancer and antibacterial properties: synthesis, interaction with biological targets and mechanistic studies." Doctoral thesis, 2020. http://hdl.handle.net/2158/1186041.

Full text

Abstract:

Metal complexes show attractive features for medicinal application and may represent a versatile tool for the development of new drugs with an improved pharmacological profile. Nowadays, three platinum-based drugs are in worldwide clinical use for the treatment of many forms of cancer, while several metal compounds based on gold, ruthenium and platinum are currently in clinical trials for the treatment of neoplastic diseases or a variety of parasitic and bacterial infections. In this frame, we have decided to focus our attention on the synthesis, physico-chemical characterization and biological evaluation of some innovative metal complexes as promising candidate drugs. In particular, we have synthesized novel Pt, Ag or Au-based complexes bearing attractive anticancer and antibacterial properties, mainly through simple modification of clinically established compounds. These new compounds have been investigated using a multi-technique approach, to elucidate their physico-chemical properties and to identify their biological targets. All these compounds were also screened through a series of in biological studies either in vitro or in vivo. Overall, these new metal-based compounds showed interesting activity profiles and some of them are being considered for further pharmaceutical development.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Metal-based drugs"

1

1938-, Gielen M., ed. Metal-based anti-tumour drugs. London: Freund Pub. House, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gielen, Marcel, and Edward R. T. Tiekink, eds. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

1938-, Gielen M., and Tiekink Edward R. T, eds. Metallotherapeutic drugs and metal-based diagnostic agents: The use of metals in medicine. Hoboken, N.J: Wiley, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tiekink, Edward R., Marcel Gielen, and M. Gielen. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents. Wiley & Sons, Incorporated, John, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bhat, Irshad Ul Haq, and Zakia Khanam. Nucleic Acids: A Natural Target for Newly Designed Metal Chelate-Based Drugs. Elsevier Science & Technology Books, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tiekink, Edward R. T., and Marcel Gielen. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. Wiley & Sons, Incorporated, John, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

(Editor), Marcel Gielen, and Edward R.T. Tiekink (Editor), eds. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. Wiley, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tiekink, Edward R. T., and Marcel Gielen. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. Wiley & Sons, Incorporated, John, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Tiekink, Edward R. T., and Marcel Gielen. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine. Wiley & Sons, Incorporated, John, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lei, Peng, Scott Ayton, and Ashley I. Bush. Metal-Protein Attenuating Compounds in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0015.

Full text

Abstract:

Neurodegenerative disorders including Alzheimer’s (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are progressive diseases of the aging population with currently few therapeutic options. While aggregation and deposition of disease-specific proteins link the pathologies of these diseases, targeting these aggregating proteins with therapeutics has not yet been successful in clinical trial. This chapter profiles metals (copper, zinc, and iron) as alternative drug targets for neurodegeneration. Complex changes to metals occur in these neurodegenerative diseases. Accumulating evidences have demonstrated that perturbations to metal homeostasis contribute to the progression of neuronal dysfunction and death. Importantly, several phase II trials have shown that correcting metal dyshomeostasis improves clinical outcomes; the chapter argues that it is now time to explore the therapeutic utility of metal-based drugs in larger, phase III trials.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Metal-based drugs"

1

Brabec, Viktor, and Jana Kasparkova. "78Pt Platinum-Based Drugs." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 489–506. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dubler, Erich. "22Ti Anti-Tumor Titanium Drugs." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 125–42. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rana, Geeta, Kamesh Vyakaranam, John A. Maguire, and Narayan S. Hosmane. "5B Boron Compounds as Therapeutic Drugs." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 19–49. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kenny, Reece G., and Celine J. Marmion. "CHAPTER 1. Enhancing the Therapeutic Potential of Platinum-based Anticancer Agents by Incorporating Clinically Approved Drugs as Ligands." In Metal-based Anticancer Agents, 1–30. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016452-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Burford, Neil, and Melanie D. Eelman. "83Bi Bismuth-Based Pharmaceuticals." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 529–40. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Marcelino, Paulo Ricardo Franco, Mariete Barbosa Moreira, Talita Martins Lacerda, and Silvio Silvério da Silva. "Metal-Based Drugs for Treatment of Malaria." In Biomedical Applications of Metals, 167–93. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-74814-6_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Yei Ho, Soo, and Edward R. T. Tiekink. "79Au Gold-Based Metallotherapeutics: Use and Potential." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 507–27. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wu, Xiang, and Mei Lin Go. "26Fe The Use of Iron-Based Drugs in Medicine." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 179–200. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Carland, Michael, and Tahli Fenner. "34Se The Use of Selenium-Based Drugs in Medicine." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 313–32. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Williams, Robin S. B., and Adrian J. Harwood. "3Li Lithium Metallotherapeutics." In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 1–17. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470864052.ch1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Metal-based drugs"

1

Milaeva, E. "STATE-OF-THE-ART APPROACHES TO CREATING METAL-BASED DRUGS." In MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tripti, A. Kumar, M. Darkazanli, M. Maleva, M. Rajkumar, and L. B. Bruno. "Metal and drought tolerant biochar based biofertilizer for enhanced growth of Raphanus sativus." In MODERN SYNTHETIC METHODOLOGIES FOR CREATING DRUGS AND FUNCTIONAL MATERIALS (MOSM2020): PROCEEDINGS OF THE IV INTERNATIONAL CONFERENCE. AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0069290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Soldatovic, Tanja. "Novel perspective of anticancer metal-based drugs: Characteristics of heterometallic complexes and their potential applications." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Stephan, Chady, Ruth Merrifield, and Stefan Wilhelm. "Abstract 2988: Quantifying the Uptake of Metal Based Cancer Therapy Drugs Using Single Cell ICP-MS." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Stephan, Chady, Ruth Merrifield, and Stefan Wilhelm. "Abstract 2988: Quantifying the Uptake of Metal Based Cancer Therapy Drugs Using Single Cell ICP-MS." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Al-Ansari, Dana E., Nura A. Mohamed, Isra Marei, Huseyin Yalcin, and Haissam Abou-Saleh. "Assessment of Metal Organic Framework as Potential Drug Carriers in Cardiovascular Diseases." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0127.

Full text

Abstract:

Background: Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as MIL-89 as potential drug carriers in the cardiovascular system. Aims: To assess the effect of MOFs on the viability and cytotoxicity of human vascular cells and the cellular uptake in vitro, and the organ-system toxicity of MOF in vivo using the Zebrafish model. Methods: Human pulmonary endothelial cells (HPAECs) and pulmonary smooth muscle cells (HPASMCs) were treated with variable concentrations of MOFs. The viability, cytotoxicity and anti-inflammatory effects were measured using AlamarBlue, LDH assay and ELISA. The cellular uptake of MOFs were assessed using light, confocal, and transmission electron microscopes and EDS analysis. Moreover, Zebrafish embryos were cultured and treated with MOFs-nanoparticles at 0 hours post fertilization (hpf) followed by different organ-specific assays at 24, 48, and 72 hpf. Results: Although MOFs affect the viability at high concentrations, it does not cause any significant cytotoxicity on HPAECs and HPASMCs. Interestingly, MOFs were shown to have an anti-inflammatory effect. Microscopic images showed an increased (concentration-dependent) cellular uptake of MOFs and transfer to daughter cells in both cell types. Moreover, the in vivo study showed that high concentrations of MOFs delay zebrafish embryos hatching and cause heart deformation, which is currently investigated using cardiotoxicity markers. Conclusion: MOFs is a promising nanoparticle prototypes for drug delivery in the cardiovascular system with high cellular uptake and anti-inflammatory effects. Further investigations of MOFs, including diseased models and drug- loaded formulation is required.

APA, Harvard, Vancouver, ISO, and other styles

7

Jovanović-Stević, Snežana, Jovana Bogojeski, A. Caković, and B. Petrović. "NUCLEOPHILIC SUBSTITUTION REACTIONS OF THE CAFFEINE- DERIVED PT(II) AND PD(II) COMPLEXES WITH IMPORTANT BIOMOLECULES." In 1st INTERNATIONAL Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2021. http://dx.doi.org/10.46793/iccbi21.383js.

Full text

Abstract:

The application of transition metal complexes as chemotherapeutics has been presented throughout the history. Platinum-based drugs are widely used as anticancer agents with a broad range of antitumor activities. The study of the substitution reactions of metal complexes with nitrogen containing biomolecules can help to develop new antitumor drugs with improved characteristics. Kinetics of the substitution reactions of [Pt(caffeine)2Cl2] and [Pd(caffeine)2Cl2] (caffeine = 1,3,7-trimethylxanthine) complexes with biologically important ligands such as 9-methylguanine (9-MetGua) and guanosine-5’-monophosphate (5’-GMP) were studied by UV-Vis spectrophotometry and by stopped-flow technique. Kinetics measurements were performed under the pseudo-first order conditions at 37 °C and pH = 7.2 (25 mM Hepes buffer) in addition of 50 mM NaCl. The obtained results showed that all substitution reactions undergo the two reaction steps giving the [M(caffeine)2(Nu)2] (M = Pd(II) or Pt(II) and Nu = 5′-GMP or 9-MetGua) as the reaction product. Additionally, [Pd(caffeine)2Cl2] complex was more reactive compared to analogue platinum-complex, while 9-MetGua reacted faster than 5’-GMP.

APA, Harvard, Vancouver, ISO, and other styles

8

Lima, Paula Marynella Alves Pereira, Douglas Cardoso Brandão, Raquel Pereira Cruz, Priscila Capelari Orsolin, Wendell Guerra, Luiz Ricardo Goulart, Robson José de Oliveira Júnior, and Thaise Gonçalves Araújo. "A NEW COPPER TERNARY COMPLEX IS A PROMISED COMPOUND FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2011.

Full text

Abstract:

Objectives: Triple-negative breast cancer (TNBC) is a biologically aggressive tumor with poor prognosis due to the lack of effective therapeutic strategies. Although chemotherapy is widely employed, chemoresistance and severe side effects remain a challenge in controlling this breast cancer subtype. Doxorrubicin (DOX) and platinum-based drugs are commonly used in oncological regimens but with limitations. In this scenario, metallodrugs based on copper element have been emerged as novel and promised compounds, due to the presenting mechanisms of action and biodistribution different from the platinum drugs already used, and may be effective against tumors that are resistant to conventional chemotherapy. This study focuses on assessing the cytotoxic effect of new copper ternary metal complex (CBP-01) on breast cancer tumor cells. Methodology: Cell viability of human breast cell lines, MCF 10A (non-neoplastic) and neoplastic cells, MCF7, T-47D, and MDA-MB-231, was evaluated by 3-[4,5-dimethylthiazole-2-yl]2,5-diphenyltetra-zolium bromide — MTT methodology. CBP-01 was tested in different concentrations (1, 5, 10, 12.5, 25, and 50 μM) for 24, 48, and 72 h, and the cellular responses were compared with Carboplatin (CARB), Cisplatin (CIS), and DOX. Results: The dose-dependent profile was identified for the four drugs and the cell viability differed between the times of treatment. CBP-01 was effective against the tumor cell lines. Regarding the triple-negative cell line (MDA-MB231), CBP-01 was clearly more effective with lower IC50 (2.05) and higher SI (3.10) than the other compounds. Conclusion: Our data provide new prospects for TNBC treatment and may yield new directions for tumor management.

APA, Harvard, Vancouver, ISO, and other styles

9

Hong, Dae-Seok, Yong-Yong Ji, Il-Sik Kang, Kyoung-Kil Kwak, and Woo-Seog Ryu. "Regulatory Clearance of Spent Steel Drums." In ASME 2011 14th International Conference on Environmental Remediation and Radioactive Waste Management. ASMEDC, 2011. http://dx.doi.org/10.1115/icem2011-59405.

Full text

Abstract:

At KAERI (Korea Atomic Energy Institute), radioactive soil and concrete wastes with extremely low level of activity were regulatory cleared in 2008 and large amount of spent drums remained. After generation, drums having good physical integrity reused for packaging radioactive wastes and about 50 tons of drums unsuitable for reuse were stored as radioactive wastes. Having once been used for packaging regulatory cleared radioactive wastes, these spent drums were determined to be regulatory cleared. Before regulatory clearance, steel drums were radiation monitored, washed with pressurized water two times, compacted and stored at a designated area. Based on radiological dose assessment results using a recycling scenario derived from actual situation, the regulatory clearance of steel drums was permitted by the regulatory body. Treatment of the regulatory cleared drums was then committed to a scrap-metal dealer for recycling. In this study, a process of regulatory clearance for spent steel drums and a modified radiological dose assessment model for staff members of a scrap-metal dealer will be discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, Shutong, Sebastian Romo, Rafael Arthur Giorjao, Jorge Penso, Haixia Guo, Simon Yuen, Lisa Ely, and Antonio J. Ramirez. "Comparison of Ni-Steel Dissimilar Joints for Coke Drum External Weld Repairs Based on Isothermal Low-Cycle Fatigue Tests." In ASME 2021 Pressure Vessels & Piping Conference. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/pvp2021-62939.

Full text

Abstract:

Abstract Low-cycle fatigue failure has been widely accepted as the key mechanism causing damages of coke drums during cyclic thermal-mechanical loadings. Common damages of coke drums known as bulging and cracking are associated with accumulative plasticity caused by thermal and mechanical strains. External repairs using temper-bead welding techniques are implemented to repair welds in the damaged areas of coke drums, which provide structural support to the vessels. Compared with matching filler metals, Ni-base fillers including alloy 625 and alloy 182 are compatible with both low-alloy steel base metal and internal clads in terms of weldability and thermal expansion. However, the differences of yield strengths and cyclic hardening behaviors of nickel-base alloys from base metals compromise the fatigue resistances of weld joints. In this study, alloy 182 and alloy 625 repair coupons were evaluated and compared based on isothermal low-cycle fatigue tests. Low-cycle fatigue behaviors of both weld metals and 1.25Cr-0.5Mo base metal were measured at 1.0%, 1.5% and 2.0% strain amplitudes. Test results indicate both nickel-base filler metals exhibit overmatching strength over the base metal due to cyclic hardening. Low-cycle fatigue tests of Heat Affected zone (HAZ) samples show the failures of alloy 625 weld joints occur in the base metal, while the failures of alloy 182 weld joints occur along the fusion boundary. The observations show strength mismatch and fatigue resistance are the key factors to determine failure locations of the joints. In addition, cyclic hardening coefficients based on kinematic hardening model were extracted from experimental data to simulate the cyclic behaviors of the weld joints. Finite element simulation results were shown to be consistent with experimental data at stabilized cycles. Cyclic behaviors of weld metal and base metal within a weld transition sample were calculated based on the numerical model.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Metal-based drugs"

1

Opella, Stanley J. Development of protein based bioremediation and drugs for heavy metal toxicity. Office of Scientific and Technical Information (OSTI), September 2001. http://dx.doi.org/10.2172/805797.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!